Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

 

Search in our Online Store

Press Room
press_room.png
Date Item Title
28 Mar 2008 Cancer and TNF antibodies boost Biologics Sales in 2007
11 Feb 2008 2008 is a decisive year for the validation of the asthma target interleukin-13
23 Jul 2007 114 Blockbuster Drugs Accounted for 2006 Sales of US$ 233.7 bln
30 May 2007 The imminent change of the antithrombotics market
02 May 2007 Up and down with cholesterol management
25 Apr 2007 Beyond biogenerics: the real threats for therapeutic proteins
15 Mar 2007 La Merie and PharmaPlus team up to provide No-Frills business intelligence solutions
08 Mar 2007 Weight management is not enough for cannabinoid type 1 (CB1) receptor antagonists to become a commercial success
01 Mar 2007 The new class of dipeptidyl peptidase IV (DPP-IV) inhibitors has one clear leader and many followers
26 Feb 2007 TOP Classes of Biologics with 2006 Sales of US$ 63.8 bln
14 Feb 2007 The market of recombinant coagulation factors is growing with next generation products
05 Feb 2007 Dosing convenience is mandatory to keep pace in the pipeline race of GLP-1 analogs for type 2 diabetes
02 Feb 2007 Overview On 2006 Sales Of TOP 20 Biologics To Be Released On February 26
11 Jan 2007 The right balance drives the field of PPAR agonist R&D
19 Sep 2006 Delivery improvements of the AMD-drug Lucentis on the way
07 Sep 2006 Biologics define new standard of therapy in psoriasis
16 Aug 2006 The Crowded Field of VEGF and VEGF-R Targeting Drugs
01 Aug 2006 A Full Pipeline of Follow-on TNF-Antagonists
19 Jun 2006 Biogenerics and new technologies compete with 1st generation major protein products
02 Jun 2006 Imminent launches of new EPO products and consolidation of the biogenerics field
30 May 2006 Localized delivery of PDE-4 inhibitors to open the therapeutic window
18 May 2006 The next generation of interferons needs improvement in efficacy and safety
09 May 2006 RNA interference (RNAi) is coming of age as a therapeutic modality
13 Mar 2006 The irresistible sirena's chant of needle-free insulins
06 Mar 2006 Antibodies are the first wave of IGF-1R antagonists for cancer therapy
22 Feb 2006 Dawn has broken for obesity treatment with cannabinoid receptor (CB1) antagonists
14 Feb 2006 TOP 20 Biologics now with sales of US$ 37.7 bln in 2005
07 Feb 2006 Dosing convenience mandates the pipeline of glucagon-like peptide-1 (GLP-1) analogs for type 2 diabetes
31 Jan 2006 Emerging diabetes drugs in early development
24 Jan 2006 High interest in inhibitors of the novel target sodium-dependent glucose (co-) transporter (SGLT) for therapy of type 2 diabetes
18 Jan 2006 Tight race to be the first in a new class of dipeptidyl peptidase IV (DPP-IV) inhibitors for the oral treatment of type 2 diabetes
15 Nov 2005 Competition is needed in the follicle stimulating hormone (FSH) market
01 Nov 2005 Thrombolytic therapy needs innovation
26 Oct 2005 A biogeneric company leads the field of next generation human growth hormone (hGH)
18 Oct 2005 Too many companies with biogeneric G-CSF products compete for a small market
11 Oct 2005 Smaller is better for thrombopoiesis-stimulating agents
07 Oct 2005 Patent expiry of epoetin alfa in Europe attracts 10 companies with biogeneric erythropoietin
 
<< Start < Prev 1 Next > End >>
Results 1 - 37 of 37

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Antiviral Antibodies

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonistgs & Antagonists

Order Now

Subscribe La Merie Biologics